Cargando…
Effects of immunisation against PCSK9 in mice bearing melanoma
INTRODUCTION: Inhibition of proprotein convertase subtilisin/kexin 9 (PCSK9) is an established modality for the treatment of hypercholesterolaemia. However, the impact of PCSK9 inhibition in other situations such as cancer remains largely unknown. The current study was conducted to study the effects...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963136/ https://www.ncbi.nlm.nih.gov/pubmed/32051723 http://dx.doi.org/10.5114/aoms.2020.91291 |
_version_ | 1783488216697929728 |
---|---|
author | Momtazi-Borojeni, Amir Abbas Nik, Maryam Ebrahimi Jaafari, Mahmoud Reza Banach, Maciej Sahebkar, Amirhossein |
author_facet | Momtazi-Borojeni, Amir Abbas Nik, Maryam Ebrahimi Jaafari, Mahmoud Reza Banach, Maciej Sahebkar, Amirhossein |
author_sort | Momtazi-Borojeni, Amir Abbas |
collection | PubMed |
description | INTRODUCTION: Inhibition of proprotein convertase subtilisin/kexin 9 (PCSK9) is an established modality for the treatment of hypercholesterolaemia. However, the impact of PCSK9 inhibition in other situations such as cancer remains largely unknown. The current study was conducted to study the effects of PCSK9 inhibition on cancer endpoints in mice bearing melanoma. MATERIAL AND METHODS: To generate antiPCSK9 antibody in vivo, a nanoliposomal antiPCSK9 vaccine adsorbed to 0.4% Alum adjuvant was subcutaneously injected in C57BL/6 mice four times with bi-weekly intervals. Two weeks after the last immunisation, mice were subcutaneously inoculated with B16F0 melanoma cells. After a tumour mass was palpable (approximately 10 mm(3)), the mice were randomly divided into four groups and subjected to different treatment protocols: (1) PBS (untreated control), (2) vaccine group, (3) the combination of vaccine and a single dose of liposomal doxorubicin (Doxil(®)), and (4) liposomal doxorubicin (positive control) group. To determine therapeutic efficacy, mouse body weight, tumour size, and survival were monitored every three days for 36 days. RESULTS: The nanoliposomal antiPCSK9 vaccine was found to efficiently induce specific antibodies against PCSK9 in C57BL/6 mice, thereby reducing plasma levels and function of PCSK9. Tumour volumes in the vaccinated group were not significantly different from those in the liposomal doxorubicin, combination, and control groups. The time to reach endpoint (TTE) values of the vaccine (28 ±5 days), combination (30 ±6 days), liposomal doxorubicin (34 ±2 days), and control (31 ±2 days) groups were not significantly different, either. Furthermore, the tumour growth delay (TGD) values of the vaccine (–11.5 ±15.4%), liposomal doxorubicin (7.75 ±6.5%), combination (–6 ±20.77%), and control (0 ±7.5) groups were not significantly different. Finally, there was no significant difference between the median survival time and lifespan of the vaccinated versus other tested groups. CONCLUSIONS: The nanoliposomal PCSK9 vaccine did not adversely affect the growth of melanoma tumour nor the survival of tumour-bearing mice. |
format | Online Article Text |
id | pubmed-6963136 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-69631362020-02-12 Effects of immunisation against PCSK9 in mice bearing melanoma Momtazi-Borojeni, Amir Abbas Nik, Maryam Ebrahimi Jaafari, Mahmoud Reza Banach, Maciej Sahebkar, Amirhossein Arch Med Sci Experimental Research INTRODUCTION: Inhibition of proprotein convertase subtilisin/kexin 9 (PCSK9) is an established modality for the treatment of hypercholesterolaemia. However, the impact of PCSK9 inhibition in other situations such as cancer remains largely unknown. The current study was conducted to study the effects of PCSK9 inhibition on cancer endpoints in mice bearing melanoma. MATERIAL AND METHODS: To generate antiPCSK9 antibody in vivo, a nanoliposomal antiPCSK9 vaccine adsorbed to 0.4% Alum adjuvant was subcutaneously injected in C57BL/6 mice four times with bi-weekly intervals. Two weeks after the last immunisation, mice were subcutaneously inoculated with B16F0 melanoma cells. After a tumour mass was palpable (approximately 10 mm(3)), the mice were randomly divided into four groups and subjected to different treatment protocols: (1) PBS (untreated control), (2) vaccine group, (3) the combination of vaccine and a single dose of liposomal doxorubicin (Doxil(®)), and (4) liposomal doxorubicin (positive control) group. To determine therapeutic efficacy, mouse body weight, tumour size, and survival were monitored every three days for 36 days. RESULTS: The nanoliposomal antiPCSK9 vaccine was found to efficiently induce specific antibodies against PCSK9 in C57BL/6 mice, thereby reducing plasma levels and function of PCSK9. Tumour volumes in the vaccinated group were not significantly different from those in the liposomal doxorubicin, combination, and control groups. The time to reach endpoint (TTE) values of the vaccine (28 ±5 days), combination (30 ±6 days), liposomal doxorubicin (34 ±2 days), and control (31 ±2 days) groups were not significantly different, either. Furthermore, the tumour growth delay (TGD) values of the vaccine (–11.5 ±15.4%), liposomal doxorubicin (7.75 ±6.5%), combination (–6 ±20.77%), and control (0 ±7.5) groups were not significantly different. Finally, there was no significant difference between the median survival time and lifespan of the vaccinated versus other tested groups. CONCLUSIONS: The nanoliposomal PCSK9 vaccine did not adversely affect the growth of melanoma tumour nor the survival of tumour-bearing mice. Termedia Publishing House 2019-12-31 /pmc/articles/PMC6963136/ /pubmed/32051723 http://dx.doi.org/10.5114/aoms.2020.91291 Text en Copyright: © 2019 Termedia & Banach http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | Experimental Research Momtazi-Borojeni, Amir Abbas Nik, Maryam Ebrahimi Jaafari, Mahmoud Reza Banach, Maciej Sahebkar, Amirhossein Effects of immunisation against PCSK9 in mice bearing melanoma |
title | Effects of immunisation against PCSK9 in mice bearing melanoma |
title_full | Effects of immunisation against PCSK9 in mice bearing melanoma |
title_fullStr | Effects of immunisation against PCSK9 in mice bearing melanoma |
title_full_unstemmed | Effects of immunisation against PCSK9 in mice bearing melanoma |
title_short | Effects of immunisation against PCSK9 in mice bearing melanoma |
title_sort | effects of immunisation against pcsk9 in mice bearing melanoma |
topic | Experimental Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963136/ https://www.ncbi.nlm.nih.gov/pubmed/32051723 http://dx.doi.org/10.5114/aoms.2020.91291 |
work_keys_str_mv | AT momtaziborojeniamirabbas effectsofimmunisationagainstpcsk9inmicebearingmelanoma AT nikmaryamebrahimi effectsofimmunisationagainstpcsk9inmicebearingmelanoma AT jaafarimahmoudreza effectsofimmunisationagainstpcsk9inmicebearingmelanoma AT banachmaciej effectsofimmunisationagainstpcsk9inmicebearingmelanoma AT sahebkaramirhossein effectsofimmunisationagainstpcsk9inmicebearingmelanoma |